<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869674</url>
  </required_header>
  <id_info>
    <org_study_id>OCD-200804</org_study_id>
    <secondary_id>CBCSG-001a</secondary_id>
    <nct_id>NCT00869674</nct_id>
  </id_info>
  <brief_title>GeneSearch™ Breast Lymph Node (BLN) Assay China Registration Study</brief_title>
  <official_title>一项比较GeneSearch 乳腺淋巴结（BLN）检测试剂盒和永久病理切片检测乳腺癌患者腋窝前哨淋巴结转移的前瞻性、多中心临床试验 A Prospective and Multi-center Clinical Trial By Comparing GeneSearch™ Breast Lymph Node (BLN) Test Kit To Permanent Pathological Section On Detecting Axillary Sentinel Lymph Node Metastases In Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Medical, China</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Medical, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to compare GeneSearch™ Breast Lymph Node (BLN) Test
      Kit to permanent pathological section, so as to evaluate the clinical sensitivity and
      specificity of GeneSearch™ Breast Lymph Node (BLN) Test Kit in detecting axillary sentinel
      lymph node metastases in breast cancer patients.

      The secondary objective of this trial is to evaluate the positive predictive value and
      negative predictive value of GeneSearch™ Breast Lymph Node (BLN) Test Kit when used in the
      detection of axillary sentinel lymph node metastases in breast cancer patients.

      Prospective and multi-center clinical trial
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigational products has been suspended from the US market
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare GeneSearch™ BLN Test Kit to permanent pathological section to evaluate the clinical sensitivity and specificity of GeneSearch™ BLN Test Kit in detecting axillary sentinel lymph node metastases in breast cancer patients.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the positive predictive value and negative predictive value of GeneSearch™ BLN Test Kit when used in the detection of axillary sentinel lymph node metastases in breast cancer patients.</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">540</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Routine pathologic method</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Half of each sentinal lymph node will have rountine pathologic examination as normal practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GeneSearch BLN Assay</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half of each sentinal lymph node will have GeneSearch BLN testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>GeneSearch™ Breast Lymph Node (BLN) Assay</intervention_name>
    <description>Each of the sentinal lymph node will be divided in half according to cutting scheme.
Half of the sentinal lymph node will be tested using rountine pathological method as normal practice, half of the node will have GeneSearch BLN testing.</description>
    <arm_group_label>GeneSearch BLN Assay</arm_group_label>
    <other_name>GeneSearch</other_name>
    <other_name>Pathology</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed previously as breast cancer

          -  patient scheduled for sentinel lymph node dissection

          -  18 years or older

          -  female or male, and

          -  able and willing to give consent to participate in the study

        Exclusion Criteria:

          -  Patients taking part in other research studies that would interfere with their full
             participation in this study, or

          -  Prior sentinel or partial axillary lymphadenectomy on the same body side
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongsheng Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100035</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangdong</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second affiliated hospital of Zhongshan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Shandong Cancer hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Sichuan</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer. 1978 Mar;41(3):1170-8.</citation>
    <PMID>638961</PMID>
  </reference>
  <reference>
    <citation>Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983 Nov 1;52(9):1551-7.</citation>
    <PMID>6352003</PMID>
  </reference>
  <reference>
    <citation>Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, Shivers S, Berman C, Wells K, Rapaport D, Shons A, Horton J, Greenberg H, Nicosia S, Clark R, Cantor A, Reintgen DS. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996 Dec 11;276(22):1818-22.</citation>
    <PMID>8946902</PMID>
  </reference>
  <reference>
    <citation>Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995 Sep;222(3):394-9; discussion 399-401. Review.</citation>
    <PMID>7677468</PMID>
  </reference>
  <reference>
    <citation>Morton DL. Intraoperative lymphatic mapping and sentinel lymphadenectomy: community standard care or clinical investigation? Cancer J Sci Am. 1997 Nov-Dec;3(6):328-30. Review.</citation>
    <PMID>9403042</PMID>
  </reference>
  <reference>
    <citation>Yared MA, Middleton LP, Smith TL, Kim HW, Ross MI, Hunt KK, Sahin AA. Recommendations for sentinel lymph node processing in breast cancer. Am J Surg Pathol. 2002 Mar;26(3):377-82.</citation>
    <PMID>11859211</PMID>
  </reference>
  <reference>
    <citation>Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 2000 Feb 1;88(3):608-14.</citation>
    <PMID>10649254</PMID>
  </reference>
  <reference>
    <citation>Treseler PA, Tauchi PS. Pathologic analysis of the sentinel lymph node. Surg Clin North Am. 2000 Dec;80(6):1695-719. Review.</citation>
    <PMID>11140868</PMID>
  </reference>
  <reference>
    <citation>Van Diest PJ, Torrenga H, Borgstein PJ, Pijpers R, Bleichrodt RP, Rahusen FD, Meijer S. Reliability of intraoperative frozen section and imprint cytological investigation of sentinel lymph nodes in breast cancer. Histopathology. 1999 Jul;35(1):14-8.</citation>
    <PMID>10383709</PMID>
  </reference>
  <reference>
    <citation>Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, Costa A, de Cicco C, Geraghty JG, Luini A, Sacchini V, Veronesi P. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997 Jun 28;349(9069):1864-7.</citation>
    <PMID>9217757</PMID>
  </reference>
  <reference>
    <citation>Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S, Robertson C, Sacchini V, Veronesi P, Orvieto E, De Cicco C, Intra M, Tosi G, Scarpa D. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 1999 Feb 17;91(4):368-73.</citation>
    <PMID>10050871</PMID>
  </reference>
  <reference>
    <citation>Viale G, Bosari S, Mazzarol G, Galimberti V, Luini A, Veronesi P, Paganelli G, Bedoni M, Orvieto E. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer. 1999 Jun 1;85(11):2433-8.</citation>
    <PMID>10357414</PMID>
  </reference>
  <reference>
    <citation>Anderson TJ. The challenge of sentinel lymph node biopsy. Histopathology. 1999 Jul;35(1):82-4. Review.</citation>
    <PMID>10383718</PMID>
  </reference>
  <reference>
    <citation>Krag D. Current status of sentinel lymph node surgery for breast cancer. J Natl Cancer Inst. 1999 Feb 17;91(4):302-3.</citation>
    <PMID>10050858</PMID>
  </reference>
  <reference>
    <citation>Turner RR, Hansen NM, Stern SL, Giuliano AE. Intraoperative examination of the sentinel lymph node for breast carcinoma staging. Am J Clin Pathol. 1999 Nov;112(5):627-34.</citation>
    <PMID>10549249</PMID>
  </reference>
  <reference>
    <citation>Lockett MA, Metcalf JS, Baron PL, O'Brien PH, Elliott BM, Robison JG, Cole DJ. Efficacy of reverse transcriptase-polymerase chain reaction screening for micrometastic disease in axillary lymph nodes of breast cancer patients. Am Surg. 1998 Jun;64(6):539-43; discussion 543-4.</citation>
    <PMID>9619175</PMID>
  </reference>
  <reference>
    <citation>Julian TB, Blumencranz P, Deck K, Whitworth P, Berry DA, Berry SM, Rosenberg A, Chagpar AB, Reintgen D, Beitsch P, Simmons R, Saha S, Mamounas EP, Giuliano A. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol. 2008 Jul 10;26(20):3338-45. doi: 10.1200/JCO.2007.14.0665.</citation>
    <PMID>18612150</PMID>
  </reference>
  <reference>
    <citation>Bernstein JL, Godbold JH, Raptis G, Watson MA, Levinson B, Aaronson SA, Fleming TP. Identification of mammaglobin as a novel serum marker for breast cancer. Clin Cancer Res. 2005 Sep 15;11(18):6528-35.</citation>
    <PMID>16166429</PMID>
  </reference>
  <reference>
    <citation>Zehentner BK, Carter D. Mammaglobin: a candidate diagnostic marker for breast cancer. Clin Biochem. 2004 Apr;37(4):249-57. Review.</citation>
    <PMID>15003725</PMID>
  </reference>
  <reference>
    <citation>Schoenfeld A, Kruger KH, Gomm J, Sinnett HD, Gazet JC, Sacks N, Bender HG, Luqmani Y, Coombes RC. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer. 1997 May;33(6):854-61.</citation>
    <PMID>9291805</PMID>
  </reference>
  <reference>
    <citation>Backus J, Green GA, XU M, et al. Intra-operative molecular analysis of sentinel lymph nodes for the management of breast Cancer surgery. Clin Cancer Res; 2005</citation>
  </reference>
  <reference>
    <citation>Turner RR, Weaver DL, Cserni G, Lester SC, Hirsch K, Elashoff DA, Fitzgibbons PL, Viale G, Mazzarol G, Ibarra JA, Schnitt SJ, Giuliano AE. Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. J Clin Oncol. 2008 Jan 10;26(2):258-63. doi: 10.1200/JCO.2007.13.0179.</citation>
    <PMID>18182666</PMID>
  </reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GeneSearch</keyword>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

